

[Home](#) / [Archives](#) / Vol. 15 No. 1 (2021): Indian Journal of Forensic Medicine & Toxicology

Vol. 15 No. 1 (2021): Indian Journal of Forensic Medicine & Toxicology



DOI: <https://doi.org/10.37506/ijfmt.v15i1>

Published: 2021-01-08

Articles

Deleted

1609-1618

Socio-Demographic Profile of Fatal Poisoning in a Tertiary Care Teaching Hospital of Coimbatore District-A Retrospective Study

Angayarkanni S1 , Jeyasingh T2

1-6



Impact of Pilates Training versus Progressive Muscle Relaxation Technique on Quality of Life in Menopausal Women- A Comparative Study

Anjali Bais1 , Pratik Phansopkar2

7-11



Comparison of Muscle Length in Dominant Versus NonDominant Lower Extremity in Young Asymptomatic Individuals- A Research Protocol

Anushree Pawar¹ , Pratik Phansopkar² , KiranKumar³

12-16



Isoniazid Mono Resistance: Changing Trends in Drug Resistant Pulmonary Tuberculosis. – A Case Series of 3 Patients

Arti D. Shah¹ , Anchal Jain² , Apoorva³ , Kusum V. Shah⁴ , Yash Rana⁵ , Saket kumar⁶

17-19



Study on Effectiveness of Chakramarda (Cassia tora) Ghrít and Go-Ghrít in the Management of Parikartika (Fissure in Ano)

Alok Kumar Diwedi¹,Alok Kumar Diwedi¹, Kiran Khandare² , Pooja Shrivastav³ Kiran Khandare² , Pooja Shrivastav³

20-24



Percutaneous Subclavian Artery Covered Stent Placement Following Inadvertent Subclavian Arterial Cannulation

Cinosh Mathew¹ , R Calton²

26-30



Correlation of Vitamin D level with severity of Coronary Artery Disease(CAD) in patients of Acute Coronary Syndrome(ACS) in a Tertiary Care Centre in Western India

Cinosh Mathew¹ , Nishant Saxena² , Ashish Sharma² , Jayesh Rawal³

31-37



A Questionnaire-Based Study to Evaluate the Basic Understanding of Pharmacovigilance of the Under Graduate Medical Students of a Rural Teaching Hospital

Ervilla E. Dass¹ , Maulin Mehta² , Jayant Patharkar³

38-43



Assessing Fear-Avoidance Belief Questionnaire and Quality of Life in Housewives with Knee Osteoarthritis : A Research Protocol

Dhanashri R Ghordadekar¹ , Angela Kapoor²

44-49

 PDF

Effect of *Malus sylvestris* Extract on Histopathological Features of Hypercholesterolemic Wistar Rat (*Rattus norvegicus*) Fatty Liver

Nadhifa Tanesha Aufazhafarin¹ , Alphania Rahniayu² , Ema Qurnianingsih³ , Arifa Mustika⁴
1367-1372

 PDF

Hyperglycemia in Childhood Acute Lymphoblastic Leukemia During Induction Chemotherapy

Nengcy Erlina Tasik Rerung¹, Andi Cahyadi² , Nur Rochmah³ , Maria Christina Shanty Larasati⁴, Mia Ratwita Andarsini⁵ , Muhammad Faizi⁶

1373-1378

 PDF

Correlation of Hot Work Climate with Dehydration on Bricks Workers

Nesya Shera Putri Iksani¹ , Endang Dwiyaniti²

1379-1386

 PDF

Equality of Suffrage for People with Mental Disorders in Malang City

Nofi Sri Utami¹ , Nanik Prasetyoningsih², Kuswanto Kuswanto³

1387-1391

 PDF

Determining the Exposure of Benzene, Toluene, Xylene (in Condensate) in a Chemical Laboratory of Natural Gas Company by Chemical Health Risk Assessment (CHRA)

Nora Putri Sabilla¹ , Noeroel Widajati²

1392-1397

 PDF

A questionnaire-based Study of Knowledge and Attitude in Healthcare Professionals about Child Sexual Abuse related to POCSO (Protection of Children from Sexual Offences) Act: A Cross-sectional Study

Nowsheen Goni¹ , Mukesh Kumar Goyal² , Chahat Shikarwar³ , Chahat Jangir⁴

1398-1405

 PDF

Level of Knowledge and Family Support toward Medication Adherence among Patient with Diabetes Mellitus in Malang, Indonesia

Nur Lailatul Masruroh^{1*}, Alifia Fatehana Pangastuti² , Nur Melizza¹ , Anggraini Dwi Kurnia¹

[Home](#) / Editorial Team

Editorial Team

Editor in Chief

Prof S K Dhattarwal

Forensic Medicine, PGIMS, Rohtak, Haryana

E-mail: editor.ijfmt@gmail.com

EDITORIAL ADVISORY BOARD

1. Prof Sudhir K Gupta, Head, FMT. AIIMS, New Delhi , India
2. Prof Mete Gulmen ,Cukurova University, TURKEY
3. Prof. Leandro Duarte De Carvalho , Minas Gerais, Belo Horizonte, BRAZIL
4. Dr. Valery Gunas, National Pirogov Memorial Medical University,Vinnitsya, UKRAINE
5. Dr. Rahul Pathak Forensic Science, Dept of Life Sciences ,Anglia Ruskin University, Cambridge, UNITED KINGDOM
6. Prof Emilo Nuzzalese, University of Turin , Italy
7. Dr Noha A. Magdy Elrafie, Forensic Toxicology, Ain Shams University, Cairo, EGYPT
8. Dr Rituja Sharma, Associate Prof, Law, Banasthali Vidyapeeth Jaipur
9. Dr Shankar Bakkanwar (*Associate Professor*) Forensic Medicine, Kasturba Medical College, Manipal, Karnataka
10. Dr K. Ravikumar , Raksha Shakti University, Ahmedabad, Gujrat.
11. Dr C. Behera (*Addl. Prof*) Dept of FMT, AIIMS, New Delhi
12. Dr. Kanak Lata Verma, Deputy Director, Toxicology ,RFSL, Chanakyapuri New Delhi
13. Dr. Asha Srivastava (*Senior Scientific Officer*) Forensic Psychology,Central Forensic Science Laboratory, CBI, Delhi
14. Dr. Raghvendra Kumar Vidua, (Associate Prof), FMT, AIIMS Bhopal
15. Dr. Vaibhav Saran (*Asst.Prof.*) School of Forensic Science, Sam Higginbottom Institute of Agriculture Technology & Sciences,Allahabad
16. Ms Aparna R. Asst. Prof. Forensic Serology & Biology, Jain University, Bengaluru
17. Dr. Deepali Jain, Asst Prof, Forensic Science ,BB Ambedkar University, Lucknow
18. Prof. NK Aggrawal Forensic Medicine, UCMS, Delhi
19. Prof. Manoj Kumar Mohanty, Forensic Medicine, AIIMS, Bhubneshwar, Odisha
20. Prof. Amar Jyoti Patowary, Forensic Medicine, NEIGRIHMS, Shillong, Meghalaya
21. Prof S. Venkata Raghava , Forensic Medicine, Banglore Medical College, Bengaluru
22. Prof. Shalini Gupta Oral Pathology and Microbiology, Faculty of Dental Sciences, King George Medical University, Lucknow
23. Prof. Virender Kumar Chhoker Forensic Medicine, Santosh Medical College, Ghaziabad, UP

24. Prof. Dayanand G Gannur , Forensic Medicine , Shri BM Patil Medical College, Hospital & Research centre, Bijapur, Karnataka

25. Prof Praveen Arora, Forensic Medicine, SAIMS, Indore, MP

26. Prof Barkha Gupta , Saraswathi Institute of Medical Sciences Hapur, Uttar Pradesh India

27. Prof M Prashant Apollo Medical College Hyderabad

28. Prof Dimple Patel , Anatomay, AMC MET Medical College , Ahmedabad , Gujarat

29. Dr Mohammed Nader Shalaby, Associate Professor of Biological Sciences and Sports Health Department, Faculty of Physical Education, Suez Canal University, Egypt

30 Dr. Avinash Harishchandra Waghmode

Professor and Head, Dept of Forensic Medicine and Toxicology, BKL Walawalkar Rural
Medical College Chiplun Ratnagiri

31 Dr. Anita Yadav Assistant Professor Forensic Science, SBAS Galgotias University, Greater
Noida, UP

32 Dr. Risha Jasmine Nathan *Lecturer in Forensic Chemistry Anglia Ruskin University*

East Road, Cambridge, CB1 1PT England, United Kingdom

Current Issue

ATOM 1.0

RSS 2.0

RSS 1.0

[Make a Submission](#)

Browse

[Open Journal Systems](#)

Information

[For Readers](#)

[For Authors](#)

Hyperglycemia in Childhood Acute Lymphoblastic Leukemia During Induction Chemotherapy

Nengcy Erlina Tasik Rerung¹, Andi Cahyadi², Nur Rochmah³, Maria Christina Shanty Larasati⁴,
Mia Ratwita Andarsini⁵, Muhammad Faizi⁶

¹Resident in Department of Child Health, Faculty of Medicine, Universitas Airlangga/ Dr. Soetomo General Hospital, Surabaya, Indonesia, ²Lecturer in Paediatric Hematology and Oncology Division, Department of Child Health, Faculty of Medicine, Universitas Airlangga/ Dr. Soetomo General Hospital, Surabaya, Indonesia, ³Lecturer and Consultant in Paediatric Endocrinology Division, Department of Child Health, Faculty of Medicine, Universitas Airlangga/ Dr. Soetomo General Hospital, Surabaya, Indonesia, ⁴Lecturer and Consultant in Paediatric Hematology and Oncology Division, Department of Child Health, Faculty of Medicine, Universitas Airlangga/ Dr. Soetomo General Hospital, Surabaya, Indonesia, ⁵Lecturer and Consultant in Paediatric Hematology and Oncology Division, Department of Child Health, Faculty of Medicine, Universitas Airlangga/ Dr. Soetomo General Hospital, Surabaya, Indonesia, ⁶Lecturer and Consultant in Paediatric Endocrinology Division, Department of Child Health, Faculty of Medicine, Universitas Airlangga/ Dr. Soetomo General Hospital, Surabaya, Indonesia

Abstract

Background: Hyperglycemia is a recognized side effect of the corticosteroids and asparaginase given during induction chemotherapy for pediatric acute lymphoblastic leukemia (ALL). The ALL is the malignant tumor with the highest incidence in the childhood. The aim of this study is to investigate the impact of hyperglycemia during induction chemotherapy in childhood ALL.

Methods: This prospective study was done in Dr. Soetomo hospital from January to April 2018. The subject was newly diagnosed as ALL under the age of 18 years, treated with Indonesian childhood ALL 2013 protocol (Standard Risk (SR) group and High Risk (HR) group). Hyperglycemia was defined as at least two separate random plasma glucose levels > 200 mg/dL, which was evaluated before and during induction chemotherapy. Statistical analysis using Paired T-test for parametric and Wilcoxon Test for nonparametric.

Results: Thirty-three children were enrolled, 18/33 boys with mean age 5.8 (SD 3.78) years, compromised as ALL-L1 30/33. They were treated with ALL-HR 19/33 and ALL-SR 14/33. In overall groups, the mean random blood glucose level significantly increased from 108 (SD 21.3) mg/dL to 147 (SD 48.1) mg/dL, (mean difference 38.67 mg/dL; 95% CI 18.08 to 59.26 mg/dL, P=0.008). In SR group, there was a significant increased of mean random blood glucose level from 102 (SD 13.5) mg/dL to 133 (SD 37.3) mg/dL, (mean difference 31.8 mg/dL; 95% CI 8.78 to 54.8 mg/dL; P=0.01). In HR group, the mean random blood glucose level increased from 113 (SD 51.9) mg/dL to 165 (SD 25.4) mg/dL, (mean difference 51.9 mg/dL; 95% CI 18.6 to 85.2 mg/dL, P=0.004).

Conclusion: Blood glucose level is significantly increase during induction chemotherapy in both SR and HR

Corresponding author:

Nengcy Erlina Tasik Rerung
Department of Child Health, Faculty of Medicine,
Universitas Airlangga/ Dr. Soetomo General Hospital.
Jl. Mayjen Prof. Dr. Moestopo No. 47, Airlangga,
Surabaya, East Java, Indonesia
(+62 31) 5501681, mail: nencyetrerung@yahoo.com

Indonesian childhood ALL 2013 protocol.

Keyword: Hyperglycemia, acute lymphoblastic leukemia, childhood.

Background

Hyperglycemia is a common side effect of acute lymphoblastic leukemia (ALL) therapy. It has long

been recognized as a consequence of corticosteroids (either prednisone or dexamethasone) and asparaginase, chemotherapeutic agents key to ALL treatment. These medications are usually administered concurrently in high doses during the initial induction phase of chemotherapy. As a result, hyperglycemia frequently develops during this phase, with resolution after the steroids and asparaginase have been discontinued or reduced in dose.¹⁻⁴ The potential causes may include beta cell dysfunction caused by chemotherapeutic drugs such as L-asparaginase, increased insulin resistance and hepatic gluconeogenesis induced by corticosteroids, or synergistic effects of these medications, given that these pharmacological agents are usually combined during initial induction therapy.^{1,4} The spectrum of hyperglycemia can range widely from transient isolated episodes to severe life-threatening complications such as diabetic ketoacidosis or nonketotic hyperglycemic hyperosmolar syndrome.⁵⁻⁷ Transient hyperglycemia developed during this period largely resolves as the chemotherapy is discontinued.³ However, affected children may need longer hospitalization and delay in chemotherapy; they may experience increased infective incidence and may even have poorer survival outcomes.^{8,9}

Previous studies have documented hyperglycemia induced by chemotherapy occur in 0.2- 16%. Few published data have referred to the epidemiology of treatment-related hyperglycemia in Indonesian childhood ALL. The purpose of the current study is to evaluate the incidence of hyperglycemia during the induction chemotherapy for childhood ALL in Dr. Soetomo Hospital.

Methods

This is a prospective study involving of consecutive patients, age younger than 18 years, in whom ALL was diagnosed and who were admitted to Dr. Soetomo hospital, Surabaya between January and April 2018.

We excluded patients with previously diagnosed diabetes mellitus (DM) or who were treated with glucocorticoids were also excluded. Medical records were reviewed to obtain relevant clinical data, including demographic information, such as age at diagnosis, sex, weight, height, and clinical parameters, such as initial white blood cell count (WBC), initial C-reactive protein

(CRP) level, initial plasma glucose level, immunotyping of leukemic cells, and risk classification. Hyperglycemia was defined as at least two separate random plasma glucose levels ≥ 200 mg/dL according to the published guidelines for childhood diabetes.¹⁰ Plasma glucose level was evaluated before and during induction chemotherapy. BMI was calculated by dividing weight in kilograms by height in square meters. Using reference standards from the Centers for Disease Control and Prevention (CDC), each subject's body mass index (BMI), BMI percentile for age, and BMI z-score for age were calculated. Per current CDC guidelines, subjects with BMI greater than or equal to the 95th percentile for age and gender were defined as overweight and those with BMI greater than or equal to the 85th percentile for age and gender were defined as at risk for overweight.¹¹ All patients were treated according to the Indonesian childhood ALL 2013 protocol. The 1st day of treatment was designated when the use of steroids was started. The entire procedure was approved by the Ethic Committee Dr. Soetomo Hospital, Surabaya.

All of the data collected were entered into an SPSS database (SPSS version 21.0.0.0). Descriptive statistics about the subject population were calculated, including data such as sex, age, and BMI at diagnosis. Presence of hyperglycemia was defined as above. Proportions of subjects with hyperglycemia overall and within each population category group (High risk and standard risk group) were calculated. For this analysis, subjects were divided by high risk and standard risk group as defined above. Chi-square analysis was used to determine the magnitude of difference in prevalence of hyperglycemia between groups. Statistical analysis using Paired T-test for parametric and Wilcoxon Test for non parametric. P values < 0.05 were regarded as significant.

Results

Thirty-three children were enrolled during our study period. All study subjects were newly diagnosed with ALL and received induction chemotherapy between January and April 2018. There were 18/33 boys and 15/33 were girls, the mean age of the patients when initially diagnosed was 5.8 (SD 3.78) years old. The patients compromised as ALL-L1 30/33 patients. They were treated with ALL-HR 19/33 patients and ALL-SR 14/33 patients. Baseline characteristics at the time of

testing are shown in Table 1.

In overall groups, 6/33 patients experienced hyperglycemia during induction chemotherapy, five of them treated with ALL-HR regimen and one treated with ALL-SR regimen. There is no significant incidence of hyperglycemia between ALL-HR and ALL-SR with p value 0.117 (Table 2). In overall groups, the mean random blood glucose level significantly increased from 108 (SD 21.3) mg/dL to 147 (SD 48.1) mg/dL, (mean difference 38.67 mg/dL; 95% CI 18.08 to 59.26 mg/dL, P=0.008).

Table 1. The baseline characteristics of the patients

Characteristics	Number (%)
Sex	
Male	18 (54.5)
Female	15 (45.5)
Age	
<10 y	27(81.8)
≥10 y	6 (18.2)
Nutritional status	
Undernourished	16 (48.5)
Well-nourished	16 (48.5)
Overweight	1 (3)
Obese	0
CRP	
< 20mg/dL	27 (81.8)
≥20 mg/dL	6 (18.2)
Risk group	
Standard risk	14 (42.4)
High risk	19 (57.6)

In overall groups, the mean random blood glucose level significantly increased from 108 (SD 21.3) mg/dL to 147 (SD 48.1) mg/dL, (mean difference 38.67 mg/dL; 95% CI 18.08 to 59.26 mg/dL, P=0.008). In SR group, there was a significant increased of mean random blood glucose level from 102 (SD 13.5) mg/dL to 133 (SD 37.3) mg/dL, (mean difference 31.8 mg/dL; 95% CI 8.78 to 54.8 mg/dL; P=0.01).

Table 2. Hyperglycemia in ALL HR and ALL SR

Diagnosis	Hyperglycemia		Total	P value
	Yes	No		
ALL HR	5	13	18	
ALL SR	1	14	15	
Total	6	27	33	0.117

In HR group, the mean random blood glucose level increased from 113 (SD 51.9) mg/dL to 165 (SD 25.4) mg/dL, (mean difference 51.9 mg/dL; 95% CI 18.6 to 85.2 mg/dL, P=0.004), the increased blood glucose during induction chemotherapy are demonstrated in Table 3.

Table 3. Increased blood glucose during induction chemotherapy

Groups	Before chemotherapy	During chemotherapy	Mean (95 % CI)	P value
ALL HR	113 (SD 51.9)	165 (SD 25.4)	51.9 (18.6- 85.2)	0.004
ALL SR	102 (SD 13.5)	133 (SD 37.3)	31.8 (8.78 – 54.8)	0.01
Overall	108 (SD 21.3)	147 (SD 48.1)	38.67(18.08- 59.26)	0.008

Discussion

In this study, 33 children with newly diagnosis of acute lymphoblastic leukemia that treated in Dr Soetomo hospital and were in induction chemotherapy of their treatment, evaluated for hyperglycemia. These Children followed for six weeks and were assessed for growth parameters, and blood sugar. Hyperglycemia defined when at least two random glucose level >200 mg/dl. According to these criteria, there were six cases with hyperglycemia (18% of the subjects). In a study by Banihashem et al, 32 patients with a diagnosis of acute leukemia, and 17.2% of patients had hyperglycemia.¹²

In this study, there was no significant difference between incidence of hyperglycemia and

type of treatment according to Indonesia childhood ALL protocol 2013 (chi-square p=0.117). This result similar with Banihashem study, which is there was no significant difference between incidence of hyperglycemia and different protocol of chemotherapy that used for treatment of children (chi-square p=0.983).¹² The similar study was a study by Baillargeon et al. that evaluated transient hyperglycemia in Hispanic children with Acute Lymphoblastic Leukemia, and 11.0% of the study cohort developed hyperglycemia during induction chemotherapy.⁴

In this study, the blood glucose level is significantly increase in all groups during induction chemotherapy, overall with p value 0.008, p value 0.004 and 0.01 in HR groups and SR groups, respectively.

At a literature by Lowas et al. Prevalence of transient hyperglycemia during induction chemotherapy for pediatric acute lymphoblastic leukemia was assessed. Transient hyperglycemia (TH) is a recognized side effect of the corticosteroids and asparaginase given during induction chemotherapy for pediatric acute lymphoblastic leukemia (ALL). This study examined the prevalence of TH in a cohort of pediatric ALL patients and the impact on TH of type of steroid or asparaginase.¹³

Hyperglycemia and diabetes induced by chemotherapy occur in the range of 0,2% to 16% (see table 4). Pui et al reported hyperglycemia in 9,7% of the pediatric ALL patients in the induction period of chemotherapy, after receiving prednisone and L-asparaginase.³ Weiser et al documented an incidence of hyperglycemia in 37% of patients during induction chemotherapy.¹⁴ According to Pastore et al 50% of ALL children may develop hyperglycemia, whereas Banihashem et al reported that 27,5% of the pediatric patients showed either diabetes mellitus or hyperglycemia.¹²

There is a complex pathophysiology mechanism that explains the development of hyperglycemia in the pediatric population receiving induction chemotherapy. DeFronzo et al have described a series of events that lead to genesis of diabetes as follow: 1) some patients showed a predisposition to enhance insulin resistance and propensity for β -cells failure, 2) specific risk factors such as preexisting obesity reinforce these defects, 3) diabetes mellitus comes up, when a concomitant insulin secretory defect is present, regardless of the etiology.¹⁵

During the standard treatment of ALL, children receive 3 drugs in the first month of the therapy. These include L-asparaginase, Vincristine and steroids as prednisolone. Children in high risk group of ALL receive a fourth chemotherapy drug, mostly daunorubicin. During the standard treatment of ALL, children receive 3 drugs in the first month of the therapy. Additionally, intrathecal chemotherapy using commonly methotrexate is performed. L-asparaginase inhibits insulin protein synthesis.¹⁶ L-asparaginase may directly reduce the glucose-stimulated release of insulin from β - cells and indirectly reduce insulin production by causing pancreatitis. Furthermore, it is known, that

corticosteroids induce insulin resistance. These effects may lead to the development of diabetes mellitus in children receiving chemotherapy, and more often in those with additional risk factors.^{16,17}

Hyperglycemia occurs commonly in the pediatric population receiving induction chemotherapy, but a combination of glucocorticoids and L-asparaginase may cause diabetes mellitus. Physicians should be aware of these risk factors and perform an early and careful screening for hyperglycemia (fasting glucose levels) during the treatment of the patients with ALL.¹⁸

Furthermore, application of the right treatment for hyperglycemia, such as insulin, permits an early clinical and biochemical normalization and enforces thereby the continuation of the chemotherapy. The use of insulin may reduce the period of hyperglycemia and therefore the possible future metabolic side effects.

Conclusion

The incidence of hyperglycemia is not significant in this study, but blood glucose level is significantly increase during induction chemotherapy in both SR and HR Indonesian childhood ALL 2013 protocol. Therefore, we recommend clinicians should be aware of the risk of hyperglycemia in childhood ALL during the induction chemotherapy. Future investigations of pediatric cohorts are needed to evaluate the influence and outcome of transient hyperglycemia as well as diabetes mellitus for long-term survival and metabolic syndrome.

Conflict of Interest : None declared

Funding : None declared

Ethical Clearance: Taken from Ethic Committee Dr. Soetomo Hospital, Surabaya.

References

1. Howard SC, Pui CH. Endocrine complications in pediatric patients with acute lymphoblastic leukemia. *Blood Rev.* 2002;16:225 – 43.
2. Cetin M, Yetgin S, Kara A. Hyperglycemia, ketoacidosis and other complications of L-asparaginase in children with acute lymphoblastic leukemia. *J Med.* 1994;25:219 – 29.
3. Pui CH, Burghen GA, Bowman WP. Risk factors for hyperglycemia in children with leukemia receiving

- L-asparaginase and prednisone. *J Pediatr.* 1981; 99: 46–50.
4. Baillargeon J, Langevin AM, Mullins J. Transient hyperglycemia in Hispanic children with acute lymphoblastic leukemia. *Pediatr Blood Cancer.* 2005; 45: 960–3.
 5. Roberson JR, Raju S, Shelso J, Pui CH, Howard SC. Diabetic ketoacidosis during therapy for pediatric acute lymphoblastic leukemia. *Pediatr Blood Cancer.* 2008; 50: 1207-12.
 6. Dundar B, Eren E, Oktem F, Dundar N, Tunc B, Canatan D. Hyperosmolar non-ketotic syndrome in a child associated with L-asparaginase and prednisolone. *Pediatr Int.* 2007; 49: 256-7.
 7. Venkatraman R, Jayashree M, Singhi S, Marwaha RK. Hyperglycemic hyperosmolar nonketotic syndrome in a child with acute lymphoblastic leukemia undergoing induction chemotherapy: case report. *J Pediatr Hematol Oncol.* 2005; 27: 234-5.
 8. Sonabend RY, McKay SV, Okcu MF, Yan J, Haymond MW, Margolin JF. Hyperglycemia during induction therapy is associated with poorer survival in children with acute lymphocytic leukemia. *J Pediatr.* 2009; 155: 73-8.
 9. Roberson JR, Spraker HL, Shelso J, Zhou Y, Inaba H, Metzger ML. Clinical consequences of hyperglycemia during remission induction therapy for pediatric acute lymphoblastic leukemia. *Leukemia.* 2009; 23: 245-50.
 10. Craig ME, Hattersley A, Donaghue K, International Society for Pediatric and Adolescent Diabetes. ISPAD Clinical Practice Consensus Guidelines 2006-2007. Definition, epidemiology and classification. *Pediatr Diabetes.* 2006; 7: 343-51.
 11. Developed by the National Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion. *CDC.* 2000; 11; 13-4.
 12. Banihashem A, Ghasemi A, Ghaemi N, Moazzen N, Amirabadi. A Prevalence of transient hyperglycemia and diabetes mellitus in pediatric patients with acute leukemia. *Iran J Ped Hematol Oncol.* 2014; 4: 5-10.
 13. Lowas SR, Marks D, Malempati S. Prevalence of transient hyperglycemia during induction chemotherapy for pediatric acute lymphoblastic leukemia. *Pediatr Blood Cancer.* 2009; 52: 814-8.
 14. Weiser MA, Cabanillas ME, Konopleva M. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. *Cancer.* 2004; 100: 1179-85.
 15. DeFronzo RA, Del Prato S. Insulin resistance and diabetes mellitus. *J Diabetes Complications.* 1996; 10: 243-245.
 16. Pastore G, Saracco P, Brach del Prever A, Iannacci L, Miniero R. Glucose metabolism in children with acute lymphoblastic leukemia treated according to two different L- asparaginase schedules. *Acta Haematol.* 1984; 72: 384-7.
 17. Skomra S, Przybylska T. Transient diabetes mellitus with ketoacidosis in a child during the treatment of acute lymphoblastic leukemia with L-asparaginase. *Pol Tyg Lek.* 1992; 47: 31-2.
 18. Maria Moschovi. Hyperglycemia and Diabetes Mellitus in Children with Acute Lymphoblastic Leukemia. *J Hematol Diabetes.* 2018; 2: 1-3.